Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from idiopathic overactive bladder.
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
- 12 Septembre 2024 - 1 mn de lecture
The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from idiopathic overactive bladder.
Related Clinical Trials
12 Septembre 2024
1 mn de lecture
An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in France
12 Septembre 2024
1 mn de lecture
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
12 Septembre 2024
1 mn de lecture
Evaluation of Palovarotene Concentration in Semen of Healthy Men after Multiple Oral Doses
12 Septembre 2024
1 mn de lecture
A Thorough QT Study Evaluating the Effect of a Therapeutic and a Supratherapeutic Dose of Palovarotene on Electrocardiogram Parameters
12 Septembre 2024
1 mn de lecture
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in...
12 Septembre 2024
1 mn de lecture
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
12 Septembre 2024
1 mn de lecture
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
12 Septembre 2024
1 mn de lecture
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
12 Septembre 2024
1 mn de lecture
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
12 Septembre 2024
1 mn de lecture